ImageVerifierCode 换一换
格式:PPT , 页数:32 ,大小:1.19MB ,
文档编号:429549      下载积分:10 文币
快捷下载
登录下载
邮箱/手机:
温馨提示:
系统将以此处填写的邮箱或者手机号生成账号和密码,方便再次下载。 如填写123,账号和密码都是123。
支付方式: 支付宝    微信支付   
验证码:   换一换

优惠套餐
 

温馨提示:若手机下载失败,请复制以下地址【https://www.163wenku.com/d-429549.html】到电脑浏览器->登陆(账号密码均为手机号或邮箱;不要扫码登陆)->重新下载(不再收费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录  
下载须知

1: 试题类文档的标题没说有答案,则无答案;主观题也可能无答案。PPT的音视频可能无法播放。 请谨慎下单,一旦售出,概不退换。
2: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
3: 本文为用户(金钥匙文档)主动上传,所有收益归该用户。163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

1,本文(内科精品课件:29炎症性肠病IBDe.ppt)为本站会员(金钥匙文档)主动上传,163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。
2,用户下载本文档,所消耗的文币(积分)将全额增加到上传者的账号。
3, 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(发送邮件至3464097650@qq.com或直接QQ联系客服),我们立即给予删除!

内科精品课件:29炎症性肠病IBDe.ppt

1、Inflammatory Bowel Disease,Hongyu Ren,MD Division of GI, Xiehe Hospital, Wuhan,Overview,Introduction/Epidemiology Pathogenesis Clinical Manifestations Conventional Therapies Prognosis,Introduction,Definition: Chronic autoimmune inflammatory disorders, involving some or all layers of the gut wall.,Ul

2、cerative Colitis (UC) Mucosal / submucosal only,Crohns Disease (CD) All layers of wall at risk,Ulcerative Colitis,Crohns Disease,Endoscopic Appearance,Normal colon,Friability Exudate bleeding,Diffuse ulceration,Cobblestoning,Focal ulceration,Histology/Depth of IBD,Mucosal and submucosal only No gran

3、ulomas seen,* Transmural disease * Granulomas occasionally seen,Ulcerative Colitis,Crohns Disease,Ulcerative Colitis vs Crohns Disease,Epidemiology,Incidence: 5-29 per 100,000 people per year Prevalence: 1.3 million persons New cases: estimated 20,000-100,000 per year* Gender distribution: Crohns di

4、sease: Slight female predominance Ulcerative Colitis: Slight male predominance Age incidence - Bimodal distribution Peak onset: 15 to 25 years of age Second peak incidence: 50 to 65 years of age,Anti-inflammatory,Pro-inflammatory,TNF IL-1b IL-12 / IL-18 IFNg,IL-4 / IL-13 IL-1Ra TGFb IL-10 PGE2,Patho

5、genesis,Pathogenesis of Inflammatory Bowel Disease,Immune Dysregulation,IBD,Genetic Susceptibility,Environmental Triggers,Environment,Risk factors: Occupations associated with outdoor physical labor Higher socioeconomic status Women who use oral contraceptives Increased intake of refined sugars and

6、a paucity of fresh fruits and vegetables in the diet Smoking Stress,Risk Factors,Known Family history of IBD Cigarette smoking Risk for CD Protective for UC Appendectomy Risk for CD Protective for UC,Possible Oral contraceptives Diet: sugar, fat Breastfeeding (protective) Childhood infections Measle

7、s infection Mycobacterium paratuberculosis infection,The relative risk among first-degree relatives is 14 to 15 times higher than that of the general population Ethnicity plays a role as well The concordance rate among monozygotic twins is as high as 67% for Crohns disease but only 13% to 20% for ul

8、cerative colitis,Genetics,Genetics,10-25% of patients have a 1st degree relative with IBD Lifetime risk for siblings and offspring of IBD patients: 10% Monozygotic twins often share disease pattern and age of onset Concordance CD (58%) UC (6%) Genome search loci on chromosomes 3, 5, 6, 12, 14, 16, 1

9、9,Luminal antigen,Mucosal immune System (APC),Th2,Th1,T-supp/T-reg cells,TNF-, IFN-,IL-4 IL-5 IL-10,Humoral immune response B-cell, plasma cell expansion Increased Ig secretion,Th1 vs Th2 response,Crohns Disease,Cytokine production,Resistance to normal downregulation,Tissue injury Ineffective repair

10、,Ulcerative Colitis,Healthy Colon,Cell-mediated immune response,Immune Dysregulation,Pathology,Macroscopic Features Early lesion-aphthous ulcer Later Findings-Linear or serpiginous ulcers may form in a longitudinal direction. Irregular thickening of the bowel wall and, along with hypertrophy of the

11、muscularis mucosa. Microscopic level The transmural nature of the inflammation. The presence of granulomas.,Clinical Manifestations,History,Exam,Laboratory,Endoscopy,Stool Studies,Clinical Presentation,Signs Mild or moderate disease usually look well Severe attacks: fever tachycardia abdominal tende

12、rness distension decreased bowel sounds Clubbing,Lab evaluation Acute phase reactants: ESR, CRP elevation Leukocytosis Anemia Reduced serum albumin Hypokalemia Abnormal LFTs Stool: leukocytes, RBCs,Symptoms,Crohns Disease Diarrhea (non-bloody) Weight loss Fever Perianal drainage/pus Right lower quad

13、rant pain,Ulcerative Colitis Rectal bleeding Fecal urgency / tenesmus Diarrhea (bloody) Lower abdominal cramping,Disease Distribution,Ulcerative Colitis Rectum Cecum Confluent / Contiguous Ileal involvement uncommon No perianal disease,Crohns Disease Anywhere from “mouth to anus” Segmental / Skip Le

14、sions Rectum usually spared Ileal involvement common Perianal disease common,Ulcerative Colitis distribution,Mild,Severe,30%,40%,30%,Crohns Disease distribution,Liver,Eyes,Skin,Joints,Blood,Heart,Mouth,Extraintestinal IBD,Complication-UC,Massive hemorrhage Perforation acute dilatation of the colon (

15、“toxic megacolon“) strictures pseudopolyps colonic cancer,Complication-CD,Stricture Fistula and Abscess perforation and bleeding cholelithiasis,Complications of Crohns Disease,Crohns Strictures,Complications of Crohns Disease,Crohns Fistulae,Perianal fistula,Complications of Crohns Disease,Crohns Fi

16、stulae,Entero-enteral fistula,Assessment of Disease Severity,Mildfewer than four stools daily, with or without blood, with no systemic disturbance and a normal erythrocyte sedimentation rate (ESR). Moderatemore than four stools daily but with minimal systemic disturbance. Severemore than six stools

17、daily with blood and with evidence of systemic disturbance, as shown by fever, tachycardia, anemia, or an ESR greater than 30.,Treatment Goals,Diagnosis and prompt therapeutic response Induction of complete remission Low side-effect profile to enhance compliance Maintenance of clinical remission Med

18、ical vs. surgical remission Steroid sparing Education and improvement of quality of life,Treatment,Conventional therapies: 5-ASA/SASP Corticosteroids/Budesonide Immunomodulators Antibiotics Anti-metabolites Biologic Modifiers,Prognosis,Ulcerative colitis 80% have intermittent attacks of their diseas

19、e From 10% to 15% of patients pursue a chronic continuous course,Crohn Disease Over a 4-year, 22% of patients remain in remission, 25% experience active symptoms, and 53% between active and inactive disease. The risk of colorectal cancer in Crohns disease above the general population as high as 26.6,END,

侵权处理QQ:3464097650--上传资料QQ:3464097650

【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。


163文库-Www.163Wenku.Com |网站地图|